Department of Pathology, Dunedin School of Medicine, University of Otago, P.O. Box 56, Dunedin 9016, New Zealand.
Department of Pathology, Dunedin School of Medicine, University of Otago, P.O. Box 56, Dunedin 9016, New Zealand.
Trends Cancer. 2022 Mar;8(3):226-241. doi: 10.1016/j.trecan.2021.11.008. Epub 2021 Dec 22.
Despite the development of novel therapeutic approaches and improved clinical management, survival from metastatic disease remains poor. Indeed, metastasis accounts for the vast majority of cancer-related deaths. The metastatic cascade comprises a complex range of molecular events that cannot be explained by genetic aberrations alone; dynamic, epigenetic regulatory mechanisms are now being implicated as key drivers of successful metastasis. With the emergence of CRISPR-based epigenomic editing, it is now possible to investigate the direct role of locus-specific epigenetic alterations in metastatic progression. Here, we review the role of epigenetic mechanisms in cancer metastasis, explore recent developments in technologies for epigenomic investigation, and highlight the emerging applications of epigenomic editing technologies in the clinical management of cancer.
尽管新的治疗方法和改进的临床管理不断发展,但转移性疾病的生存率仍然很差。事实上,转移是癌症相关死亡的主要原因。转移级联反应包括一系列复杂的分子事件,这些事件不能仅用遗传异常来解释;动态的、表观遗传的调节机制现在被认为是成功转移的关键驱动因素。随着基于 CRISPR 的表观基因组编辑的出现,现在可以研究特定基因座的表观遗传改变在转移进展中的直接作用。在这里,我们回顾了表观遗传机制在癌症转移中的作用,探讨了表观基因组研究技术的最新进展,并强调了表观基因组编辑技术在癌症临床管理中的新兴应用。
Trends Cancer. 2022-3
Cancer Metastasis Rev. 2023-6
Epigenomics. 2020-7
Am J Pathol. 2016-7
Bioessays. 2021-5
Semin Cancer Biol. 2017-8-12
Curr Opin Chem Biol. 2020-8
Annu Rev Genomics Hum Genet. 2018-5-31
Nat Rev Genet. 2016-11-21
Signal Transduct Target Ther. 2025-7-18
Nat Commun. 2025-6-5
Cancer Cell Int. 2025-4-26
Cancer Metastasis Rev. 2024-11-25
Cytojournal. 2024-8-29
Mol Cancer. 2024-8-2
Front Endocrinol (Lausanne). 2024
Cancers (Basel). 2024-2-23